MedPath

Evaluating Smoking Cessation Interventions for PWH in South Africa

Phase 2
Recruiting
Conditions
Smoking Cessation
Comorbidities and Coexisting Conditions
HIV
Interventions
Behavioral: Intensive Behavioral Counselling
Behavioral: Peer Counselling
Registration Number
NCT05413122
Lead Sponsor
Johns Hopkins University
Brief Summary

The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.

Detailed Description

This project will evaluate the main and interaction effects of four evidence-based smoking cessation components integrated within HIV care in South Africa: (1) intensive behavioural counselling, (2) peer support, (3) combination nicotine replacement therapy (c-NRT), and (4) varenicline. The investigators will also evaluate the implementation and cost-effectiveness of these interventions. This study is a balanced full factorial randomised trial of 660 adults with HIV and will be implemented in two diverse sites in Gauteng, South Africa representing both peri-urban and urban settings.

Participants will be recruited via health care worker-referral or self-referral. Interested patients will be further screened for eligibility. Eligible participants will be administered written informed consent (see "Informed Consent and Assent" section below), and participants will be randomized into one of 16 study conditions for a 12-week intervention period. This will be an open-label trial; neither the participants nor study personnel will be blinded to treatment assignment post randomization, but randomization block assignment will be concealed from the study personnel who will be enrolling participants.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
660
Inclusion Criteria
  1. ≥18 years of age, and
  2. attend one of the selected study clinics, and
  3. have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and
  4. have been taking ART for at least three consecutive months (to ensure engagement in care at the recruitment clinic), and
  5. are current tobacco smokers (smoked at least 100 cigarettes in the subject's lifetime, have smoked daily for the past 30 days, have exhaled breath carbon monoxide (CO) ≥ 7 parts per million (ppm), and have a positive urine cotinine test), and
  6. either own or have household access to a mobile phone, and
  7. provide written informed consent.
Exclusion Criteria
  1. Currently (within the previous 14 days) receiving or using smoking cessation counselling or pharmacotherapy, or
  2. are unable to participate due to severity of medical illness, guided by a Karnofsky score of ≤ 40, or
  3. have a history of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure, or
  4. have generalized eczema or psoriasis, or
  5. have cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview (M.I.N.I.), or
  6. have suicide risk as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS), or
  7. are pregnant, planning to become pregnant in the next four months, lactating, or are unwilling to use effective birth control, or
  8. have a history of adverse reactions to varenicline or nicotine patch, or
  9. are not planning to continue to receive care at the clinic for the next 52 weeks.
  10. In the opinion of the attending investigator are not a candidate for the clinical trail.

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
c-NRT & Peer SupportNicotine gumc-NRT \& Peer Support
Intensive Behavioral Counseling & Peer Support & c-NRTNicotine gumIntensive Behavioral Counseling \& Peer Support \& c-NRT
Intensive Behavioral Counseling & Varenicline & c-NRTNicotine gumIntensive Behavioral Counseling \& Varenicline \& c-NRT
Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclineNicotine gumIntensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
c-NRTNicotine patchA 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.
Intensive Behavioral Counseling & c-NRTNicotine patchIntensive Behavioral Counseling \& c-NRT
Intensive Behavioral Counseling & Varenicline & c-NRTNicotine patchIntensive Behavioral Counseling \& Varenicline \& c-NRT
Intensive Behavioral Counseling & Peer Support & c-NRTNicotine patchIntensive Behavioral Counseling \& Peer Support \& c-NRT
Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclineNicotine patchIntensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
Intensive Behavioral Counseling & c-NRTNicotine gumIntensive Behavioral Counseling \& c-NRT
Peer Support & VareniclineVareniclinePeer Support \& Varenicline
Varenicline & c-NRTNicotine gumVarenicline \& c-NRT
c-NRT & Peer SupportNicotine patchc-NRT \& Peer Support
Intensive Behavioral CounsellingIntensive Behavioral CounsellingParticipants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice. \].
c-NRT & Peer Support & VareniclinePeer Counsellingc-NRT \& Peer Support \& Varenicline
Intensive Behavioral Counseling & VareniclineIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Varenicline
Intensive Behavioral Counseling & c-NRTIntensive Behavioral CounsellingIntensive Behavioral Counseling \& c-NRT
Peer SupportPeer CounsellingParticipants randomized to receive Peer Support will be engaged by participants' own peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
c-NRT & Peer Support & VareniclineNicotine gumc-NRT \& Peer Support \& Varenicline
Intensive Behavioral Counseling & Peer Support & VareniclineIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Peer Support \& Varenicline
Intensive Behavioral Counseling & Peer Support & VareniclinePeer CounsellingIntensive Behavioral Counseling \& Peer Support \& Varenicline
Intensive Behavioral Counseling & Peer Support & c-NRTPeer CounsellingIntensive Behavioral Counseling \& Peer Support \& c-NRT
c-NRTNicotine gumA 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.
Varenicline & c-NRTNicotine patchVarenicline \& c-NRT
Peer Support & VareniclinePeer CounsellingPeer Support \& Varenicline
c-NRT & Peer SupportPeer Counsellingc-NRT \& Peer Support
c-NRT & Peer Support & VareniclineNicotine patchc-NRT \& Peer Support \& Varenicline
Intensive Behavioral Counseling & VareniclineVareniclineIntensive Behavioral Counseling \& Varenicline
Intensive Behavioral Counseling & Varenicline & c-NRTIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Varenicline \& c-NRT
Intensive Behavioral Counseling & Peer SupportPeer CounsellingIntensive Behavioral Counseling \& Peer Support
Intensive Behavioral Counseling & Peer Support & c-NRTIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Peer Support \& c-NRT
Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclineIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
Intensive Behavioral Counseling & Peer SupportIntensive Behavioral CounsellingIntensive Behavioral Counseling \& Peer Support
Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclinePeer CounsellingIntensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
VareniclineVareniclineAt enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician according to randomization into the varenicline condition and participants will be provided with education on its use. Participants will be instructed to begin taking varenicline one week prior to participants' quit date and for 11 weeks following quit date. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and to monitor adherence; calls will taper to every other week after four weeks.
Varenicline & c-NRTVareniclineVarenicline \& c-NRT
c-NRT & Peer Support & VareniclineVareniclinec-NRT \& Peer Support \& Varenicline
Intensive Behavioral Counseling & Varenicline & c-NRTVareniclineIntensive Behavioral Counseling \& Varenicline \& c-NRT
Intensive Behavioral Counseling & Peer Support & VareniclineVareniclineIntensive Behavioral Counseling \& Peer Support \& Varenicline
Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclineVareniclineIntensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
Primary Outcome Measures
NameTimeMethod
7-day point prevalence tobacco abstinence at 52 weeks52 weeks

Verified by exhaled breath CO \< 7ppm and a negative urine cotinine test.

Secondary Outcome Measures
NameTimeMethod
7-day point prevalence tobacco abstinence at 26 weeks26 weeks

Verified by exhaled breath CO \< 7ppm and a negative urine cotinine test. Urine cotinine will be excluded as an indicator of abstinence for those self-reporting c-NRT use in the preceding week.

7-day point prevalence tobacco abstinence at 12 weeks12 weeks

Verified by exhaled breath CO \< 7ppm and a negative urine cotinine test. Urine cotinine will be excluded as an indicator of abstinence for those self-reporting c-NRT use in the preceding week.

Trial Locations

Locations (1)

Perinatal HIV Research Unit (PHRU)

🇿🇦

Soweto, Gauteng, South Africa

© Copyright 2025. All Rights Reserved by MedPath